Escitalopram: Discovery, Development, Safety and Pharmacovigilance
Escitalopram is the pharmacologically active S-enantiomer of citalopram, a selective serotonin reuptake inhibitor (SSRI). Its development illustrates how isolating an active stereoisomer from an established racemic drug can produce a new product requiring independent evidence of efficacy, tolerability and safety. This review traces that lifecycle through 2026 and distinguishes clinical evidence, region-specific authorisations and pharmacovigilance interpretation [1–4].
- Escitalopram: Discovery, Development, Safety and Pharmacovigilance
- 1. Discovery: the S-enantiomer of citalopram
- 2. Mechanism and pharmacokinetics
- 3. The first pivotal adult depression programme
- 4. Lifecycle milestones
- 5. Evidence should be read at the level it was generated
- 6. Adolescent depression: an extension requiring direct evidence
- 7. Generalised anxiety disorder and the 2023 paediatric evidence
- 8. Indications and dosage: the US–UK divide
- 9. Common tolerability issues and adherence
- 10. Suicidal thoughts, clinical worsening and activation
- 11. Serotonin syndrome and interacting drugs
- 12. QT prolongation: an exposure-related regulatory lesson
- 13. Hyponatraemia and syndrome of inappropriate antidiuresis
- 14. Bleeding and haemostatic interactions
- 15. Sexual dysfunction, persistence and the October 2026 UK action
- 16. Discontinuation symptoms and relapse
- 17. Pregnancy, neonatal adaptation and breastfeeding
- 18. Seizures, glaucoma and other clinically important events
- 19. Medication and formulation reconciliation
- 20. A case-based approach to pharmacovigilance
- 21. Signal evaluation in a mature generic medicine
- 22. Regulatory governance, risk minimisation and evidence
- 23. Practical review checklist
- Key Takeaways
- References
- Regulatory Note
1. Discovery: the S-enantiomer of citalopram
Citalopram contains two mirror-image molecular forms, R- and S-citalopram. Escitalopram is the isolated S form, which provides most of the racemate's serotonin transporter inhibition. The two products are not automatically interchangeable milligram for milligram. H. Lundbeck and Forest Laboratories developed escitalopram using their experience with citalopram. A contemporary review records Swedish approval in December 2001, Swiss approval in January 2002 and subsequent European national approvals. The US FDA approved Lexapro tablets in August 2002 [3,4]. These milestones concern different jurisdictions, not a single EU central authorisation.
The term single-isomer switch describes a medicinal-chemistry strategy. It does not prove superiority to every citalopram regimen or remove established SSRI risks. Those questions require clinical data.
2. Mechanism and pharmacokinetics
Escitalopram inhibits the presynaptic serotonin transporter (SERT), increasing serotonergic signalling. The UK SmPC describes binding at the primary transporter site and a lower-affinity allosteric site. The mechanism explains a range of therapeutic and adverse effects but does not establish that depression is caused by a simple measurable serotonin deficiency [1,2].
Escitalopram is generally administered once daily; its elimination half-life after repeated dosing is about 30 hours, with steady state reached in approximately one week. Hepatic metabolism involves CYP2C19, CYP3A4 and CYP2D6. Exposure varies with age, hepatic function, genetic metabolism and interacting drugs. The UK SmPC reports approximately 50% higher exposure in older adults, 60% higher exposure with mild-to-moderate hepatic impairment and about twice the plasma concentration in CYP2C19 poor metabolisers [2]. These are exposure comparisons, not estimates of adverse-event incidence.
The CYP2C19 inhibitor omeprazole can increase escitalopram exposure. Escitalopram can also increase exposure to CYP2D6 substrates, including some antidepressants and beta-blockers [1,2]. Case assessment therefore requires the full medication chronology rather than escitalopram dose alone.
3. The first pivotal adult depression programme
In an eight-week randomised, double-blind trial of 491 outpatients, Burke and colleagues compared escitalopram 10 mg, escitalopram 20 mg, citalopram 40 mg and placebo [5]. Both escitalopram doses improved depression scores versus placebo. The authors found escitalopram 10 mg at least as effective as citalopram 40 mg in that study; this is not a universal superiority claim. The US label reports that a fixed-dose trial did not demonstrate additional mean benefit from 20 mg over 10 mg [1].
Clinical benefit develops over time and is evaluated through symptom, function and tolerability outcomes. Early improvement on a rating scale is not proof of long-term remission. Trial eligibility and short follow-up limit direct extrapolation to patients with complex comorbidity or polypharmacy.
4. Lifecycle milestones
| Period | Milestone | Interpretation |
|---|---|---|
| 2001–2002 | National European approvals and US original NDA [3,4] | Initial authorisations were region-specific |
| 2002 | Adult depression controlled studies [5] | Evidence for studied depression populations |
| 2009 | Adolescent MDD trial and US labelling [6,9] | MDD indication from age 12 in the US |
| 2011 | European review of QT prolongation [11] | Dose restrictions and interaction precautions |
| 2023 | US paediatric GAD indication and trial [7,10] | GAD from age 7 on applicable US labels |
| 2026 | UK safety-communication measures [12,13] | Stronger communication of recognised risks |
An indication extension is not the same as a safety signal, and a national approval should not be described as an EU-wide central decision.
The chronology also shows why a product's safety profile is not frozen at initial approval. Randomised trials establish efficacy in selected populations and detect common adverse reactions; wider clinical use and focused studies help clarify rare or exposure-dependent risks. A regulatory warning can be strengthened without proving that a previously unrecognised event has suddenly appeared. Conversely, the presence of an established class warning does not eliminate the need to evaluate individual escitalopram reports.
5. Evidence should be read at the level it was generated
Depression rating scales, anxiety scales, ECG changes and spontaneous adverse-event reports measure different constructs. The placebo-controlled efficacy trial supports symptom benefit over eight weeks; it cannot determine the population incidence of a rare arrhythmia. An ECG study can establish dose-related mean QTc changes but not the absolute probability of torsade de pointes in routine care. A post-marketing case may justify follow-up or signal assessment without proving causation.
These distinctions shape the remaining article: first the indication-specific clinical evidence, then product-information differences, then adverse-reaction phenotypes and operational pharmacovigilance.
6. Adolescent depression: an extension requiring direct evidence
A placebo-controlled study by Emslie and colleagues enrolled 312 adolescents aged 12–17 with major depressive disorder: 155 received escitalopram and 157 placebo for eight weeks. The mean change in the Children's Depression Rating Scale–Revised was −22.1 versus −18.8 (p=0.022, last-observation-carried-forward analysis) [6]. This is evidence of a modest group-level difference on a specified endpoint, not a guarantee of response for an individual adolescent.
The FDA's 19 March 2009 paediatric labelling record established efficacy for major depressive disorder in ages 12–17, drawing on adolescent data and other supporting evidence [9]. The short trial reported similar suicidality incidence between groups, but its size and duration could not invalidate the broader antidepressant boxed warning derived from pooled trials. That warning concerns a wider evidence base and should not be dismissed because one study was not powered to show a difference.
Treatment decisions in adolescents require attention to symptom severity, previous risk, family or caregiver involvement as appropriate, and follow-up during initiation and changes. The existence of a US adolescent MDD indication does not imply approval for all childhood psychiatric conditions or in every country.
7. Generalised anxiety disorder and the 2023 paediatric evidence
Escitalopram was studied for generalised anxiety disorder (GAD) in adults and later children. A small 2020 randomised trial in 51 adolescents found greater reduction in paediatric anxiety ratings than placebo; it also examined how CYP2C19 phenotype affected exposure [8]. That study offered supportive evidence but was too small to establish the risk profile of rare outcomes.
A subsequent multicentre, eight-week trial enrolled 275 children and adolescents aged 7–17 with GAD: 138 received escitalopram 10–20 mg daily and 137 placebo [7]. The adjusted between-group difference in change on the Pediatric Anxiety Rating Scale GAD severity measure was −1.42 points (p=0.028). Improvement on a functional measure was numerically greater but not statistically significant (p=0.286). It would be incorrect to turn the primary symptom result into a claim that every secondary endpoint improved.
The FDA's 2023 Lexapro label extended GAD treatment to patients aged 7 years and older [10]. The age limit belongs to the GAD indication; for MDD the US lower age remains 12 years on the cited 2026 label [1]. Some US generic labels continue to omit paediatric GAD information because of product-specific exclusivity wording; the actual marketed label must be checked before making a product-level assertion [1,14].
8. Indications and dosage: the US–UK divide
The US 2026 label used here lists major depressive disorder (adults and patients 12 years or older) and generalised anxiety disorder (adults and patients 7 years or older) [1]. The UK 2026 SmPC lists major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder, GAD and obsessive-compulsive disorder [2]. The UK SmPC advises that escitalopram should not be used in patients under 18 years; it does not reproduce the US paediatric authorisations. These differences are a matter of approved product information, not an argument that a trial performed in one country ceases to exist elsewhere.
| Question | Cited US label, May 2026 [1] | Cited UK SmPC, May 2026 [2] |
|---|---|---|
| Adult MDD / depressive episodes | Approved | Approved |
| Adult GAD | Approved | Approved |
| Panic, social anxiety, OCD | Not listed on cited US label | Listed indications |
| Paediatric MDD | Age 12 and older | Under-18 use not recommended |
| Paediatric GAD | Age 7 and older on this label | Under-18 use not recommended |
| Older adult dosing | 10 mg daily recommended | 10 mg daily maximum |
| Hepatic impairment | 10 mg daily recommended | Initial 5 mg, with cautious increase up to 10 mg |
The UK adult maximum is generally 20 mg/day, but the maximum is 10 mg/day in those older than 65 and in hepatic impairment [2,11]. The US label recommends 10 mg daily in elderly patients and hepatic impairment [1]. These are not instructions to prescribe a particular dose: verify the exact national product, clinical context and any newer changes.
A meaningful safety review should distinguish off-label use, medication error, product-information non-compliance and suspected adverse reaction. These categories can overlap but are not synonyms. The mere fact that a case involves an indication absent from a particular country's SmPC does not establish a causal adverse reaction.
9. Common tolerability issues and adherence
Clinical trial and product-information profiles include nausea, headache, sleep disturbance, increased sweating, fatigue and sexual dysfunction [1,2]. These may be non-serious medically yet important for adherence, quality of life and unplanned cessation. Record the starting symptoms of depression or anxiety, baseline sleep and sexual function, dose changes, concomitant treatments and whether the symptom improved after appropriate clinical management.
Patients can discontinue because of adverse effects or perceived lack of benefit. A pharmacovigilance narrative should avoid calling every treatment discontinuation a withdrawal reaction. Withdrawal or discontinuation symptoms have their own chronology and clinical features, addressed below.
10. Suicidal thoughts, clinical worsening and activation
The US boxed warning describes increased suicidal thoughts and behaviours in paediatric and young adult patients receiving antidepressants in pooled short-term studies and calls for close monitoring, especially early in treatment and after dose changes [1]. Depression and other psychiatric illnesses themselves increase suicide risk, complicating causal interpretation. The warning does not imply that all antidepressant treatment increases suicide risk at every age or that untreated illness is safer.
For a suspected case, distinguish thoughts of self-harm, preparatory behaviour, attempt and death. Obtain the pretreatment psychiatric history, previous events, contemporaneous symptoms, initiation or dose-change dates, adherence, substance exposure and major psychosocial events. Akathisia, agitation, insomnia and possible manic activation may require separate clinical characterisation. Urgent clinical assessment takes priority over administrative safety reporting when a patient is at immediate risk.
Screening for a history of bipolar disorder is important because antidepressant exposure may be associated with mania or hypomania [1,2]. The mere presence of anxiety or insomnia does not confirm a manic episode. Document mood elevation, decreased need for sleep, altered activity, duration, functional consequences and relevant co-medications.
11. Serotonin syndrome and interacting drugs
Escitalopram can contribute to serotonin syndrome, particularly with MAO inhibitors or other serotonergic drugs. The syndrome combines mental-state changes, autonomic instability and neuromuscular findings such as clonus, tremor and hyperreflexia [1]. Drug combinations involving tramadol, linezolid, other antidepressants, lithium, triptans or serotonergic supplements deserve careful chronology.
US labelling contraindicates concurrent MAOIs and pimozide, with product-specific switching instructions; the UK SmPC has additional contraindications for drugs that prolong QT [1,2]. Do not assume a single uniform washout applies to every drug or clinical circumstance. Follow-up should capture the exact medicines and administration times, objective examination, temperature, laboratory abnormalities and competing diagnoses such as infection or neuroleptic malignant syndrome. A report of nausea and agitation alone is insufficient to confirm the syndrome.
12. QT prolongation: an exposure-related regulatory lesson
The most distinctive regulatory safety issue for escitalopram is dose-dependent QTc prolongation. The UK regulator's review reported mean changes from baseline in QTcF of 4.3 ms (90% CI 2.2–6.4) at 10 mg/day and 10.7 ms (90% CI 8.6–12.8) at a supratherapeutic 30 mg/day in healthy subjects [11]. These figures show a concentration-related electrophysiological effect; they are not individual predictions or the incidence of torsade de pointes.
Post-marketing cases of QT prolongation and ventricular arrhythmia, including torsade de pointes, have been reported, especially with pre-existing cardiac risk factors, hypokalaemia or other QT-prolonging drugs [2,11]. The UK advice therefore restricts maximum doses in older adults and hepatic impairment, contraindicates treatment in known congenital long-QT or pre-existing QT prolongation, and contraindicates coadministration with medicines known to prolong the QT interval. US prescribing information is not identical in its formal contraindications, which illustrates why a single international 'escitalopram contraindication list' is unsafe.
An appropriate safety assessment asks whether the observed ECG was recorded before or after treatment, how QT was corrected for heart rate, and whether the patient had bradycardia, structural heart disease, electrolyte depletion or another QT-prolonging drug. A report of syncope should prompt consideration of arrhythmia but does not prove torsade de pointes without evidence.
Exposure, co-medication and competing causes
Escitalopram exposure can increase in older age, hepatic impairment or CYP2C19 poor metaboliser status. Omeprazole or other CYP2C19 inhibitors may further increase concentrations [2,11]. In the same patient, a loop or thiazide diuretic may contribute to hypokalaemia or hypomagnesaemia. A safety narrative that records only the escitalopram dose may miss the combined pharmacokinetic and pharmacodynamic context.
| Component | Evidence to seek | Interpretive caution |
|---|---|---|
| Drug exposure | Actual dose, start date, changes, adherence, hepatic status | Prescribed dose is not identical to systemic concentration |
| Electrocardiography | Baseline and event ECG, QT/QTc, heart rate, rhythm | Mean study QTc change is not individual torsade risk |
| Electrolytes | Potassium, magnesium, sodium, renal status | Electrolyte abnormalities may have independent causes |
| Co-medication | QT-prolonging drugs, CYP2C19 inhibitors, diuretics | Several pathways may contribute simultaneously |
| Outcome | Syncope, documented arrhythmia, treatment and recovery | Symptom reports need clinical confirmation |
13. Hyponatraemia and syndrome of inappropriate antidiuresis
Escitalopram and other SSRIs are associated with hyponatraemia, sometimes in the setting of inappropriate antidiuretic hormone activity (SIADH). Older age, diuretics and volume depletion may increase susceptibility [1,2]. Symptoms range from nausea and unsteadiness to confusion, seizures and severe neurological deterioration.
Case follow-up should obtain baseline and serial sodium, symptom onset, serum and urine osmolality when available, volume status, diuretics, endocrine and renal conditions, and response to management. Do not label every low sodium value 'confirmed SIADH': that diagnosis requires clinical and biochemical evaluation. Similarly, a normal sodium value measured weeks after an event cannot establish that the earlier symptoms were unrelated.
14. Bleeding and haemostatic interactions
Platelets acquire serotonin through uptake rather than synthesising it. Serotonin reuptake inhibition may impair platelet-related haemostasis, contributing to bleeding risk. Both US and UK product information warn about concomitant NSAIDs, aspirin, antiplatelet agents and anticoagulants [1,2]. For a bleeding event, record site, severity, haemoglobin, coagulation tests when relevant, gastrointestinal or other lesions, trauma and the complete medication list. Concomitant warfarin requires careful attention to INR as indicated in the US label.
This is principally a pharmacodynamic interaction, though changes in exposure or other medicines may coexist. Bleeding on escitalopram is not automatically caused by the antidepressant; an underlying lesion or anticoagulant regimen may be central. Conversely, intermittent over-the-counter NSAID use can be a missing risk factor in an otherwise complete prescription history.
15. Sexual dysfunction, persistence and the October 2026 UK action
Escitalopram may cause reduced libido, delayed ejaculation, orgasmic difficulty and other sexual adverse effects. Baseline sexual dysfunction can also arise from depression, anxiety, other medicines or comorbid illness. A good report establishes function before treatment, the event's onset, dose relationship, impact, cessation date and subsequent course [1,2].
The UK SmPC notes reports of sexual dysfunction persisting after SSRIs or SNRIs were discontinued [2]. On 15 October 2026, the MHRA announced stronger antidepressant patient-information measures covering suicidal thoughts and behaviours and persistent sexual dysfunction. The measures include a prominent boxed warning in the UK patient leaflet, a patient card, and a further ancillary safety leaflet planned for 2027; the term post-SSRI sexual dysfunction (PSSD) is being added to the leaflets for some medicines [12,13]. This UK leaflet presentation must not be conflated with the legal format of a US FDA boxed prescribing-information warning.
The MHRA characterised these as recognised risks for which communication is being strengthened [12]. Reports of persistent symptoms do not establish their population incidence, a single pathophysiology, or that every symptom after discontinuation is drug-caused. Follow-up should document symptom domains, duration after cessation, the original psychiatric illness, other exposures and the diagnostic evaluation without dismissing the patient's account.
16. Discontinuation symptoms and relapse
Abrupt cessation or rapid reduction can lead to dizziness, sensory disturbances, insomnia, anxiety, nausea and other discontinuation symptoms [1,2]. They may overlap with relapse of depression or anxiety but often have a different temporal relationship to missed doses or dose reduction. Product information recommends gradual reduction where possible, individualised to symptoms and clinical circumstances.
A report of 'withdrawal' should distinguish planned taper, accidental non-adherence, supply interruption, formulation changes and psychiatric recurrence. Long-standing symptoms warrant medical evaluation rather than automatic classification as a short-lived withdrawal reaction. Stopping abruptly is not an appropriate routine response to a non-emergency adverse effect.
17. Pregnancy, neonatal adaptation and breastfeeding
Pregnancy decisions balance maternal psychiatric stability with potential fetal and neonatal effects. The May 2026 US label discusses observational associations with postpartum haemorrhage after late exposure, persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation [1]. These findings are not proof that every exposed newborn will be affected, nor does the observational literature establish a specific increase in major birth defects attributable to escitalopram.
For a maternal or neonatal safety report, obtain gestational timing, dose, other medicines, maternal disease severity, obstetric factors, delivery details, neonatal signs and follow-up. Lactation assessments should capture infant age, feeding, sedation, agitation, weight and alternative explanations. A report of neonatal respiratory distress requires consideration of prematurity, infection and obstetric causes as well as maternal medication.
18. Seizures, glaucoma and other clinically important events
Escitalopram labels include precautions for seizures and angle-closure glaucoma [1,2]. A seizure report needs pre-existing epilepsy, electrolyte and metabolic findings, recent substance exposure, interacting medicines and neurologic assessment. Acute eye pain and visual disturbance require ophthalmic evaluation; headache alone does not confirm angle closure. New agitation may reflect the illness, an adverse effect, a drug interaction or bipolar activation and should be medically characterised rather than automatically assigned a single mechanism.
19. Medication and formulation reconciliation
Although escitalopram and citalopram are chemically related, they are distinct medicinal products. A prescribing, dispensing or patient-history error that confuses their names or doses may have safety consequences. Different formulations, tablet strengths and local authorisations require product-level traceability. For suspected errors, record the intended and actual medicine, strength, timing, patient exposure, clinical outcome and whether an error was intercepted before administration.
This closes the clinical risk review. The next sections translate those mechanisms and warnings into the information a pharmacovigilance team needs to assess cases, identify patterns and document defensible decisions.
20. A case-based approach to pharmacovigilance
A valid individual case safety report is not necessarily medically complete. Minimum validity and applicable reporting obligations must be assessed under the governing regulatory framework; subsequent follow-up should target facts that could change seriousness, expectedness, causal assessment or signal interpretation. EMA GVP Module VI addresses collection and management of suspected adverse-reaction reports; Module IX addresses signal management [15]. The table below is a recommended clinical follow-up aid, not an invented mandatory reporting checklist.
| Safety question | Priority follow-up | Principal alternative explanations |
|---|---|---|
| New psychiatric deterioration | Baseline severity, event description, treatment timeline, previous episodes | Illness progression, psychosocial crisis, substance exposure |
| Serotonin toxicity | Co-serotonergic medicines, clonus/hyperreflexia, temperature, onset | Infection, neuroleptic malignant syndrome, other toxidromes |
| QTc prolongation or arrhythmia | Baseline and event ECG, QT correction, electrolytes, interacting medicines | Heart disease, inherited QT disorder, electrolyte depletion |
| Hyponatraemia | Serial sodium, osmolality, volume state, diuretics, symptoms | Other causes of SIADH, renal or endocrine disease |
| Bleeding | Site, haemoglobin, anticoagulants, NSAIDs, coagulation results | Trauma, structural lesions, co-medication |
| Persistent sexual symptoms | Baseline function, symptom phenotype, stop date, longitudinal course | Underlying illness, other medicines, comorbidity |
| Neonatal complication | Trimester exposure, delivery, infant diagnosis and follow-up | Obstetric disease, prematurity, infection |
Illustrative case: a QT event after an interaction
An older adult receiving escitalopram develops syncope after initiation of another medicine and has a prolonged QTc on ECG. Review the escitalopram dose against the applicable local label, the second drug's QT and CYP effects, potassium and magnesium, heart rate, previous ECGs and underlying heart disease. A temporal association merits assessment, but syncope and a single QTc value do not independently establish drug-induced torsade de pointes. This is a hypothetical teaching case, not an actual ICSR.
Illustrative case: symptoms after dose interruption
A patient who misses several doses develops dizziness and anxiety. Document the last confirmed doses, formulation and access to medication, the original psychiatric condition, the chronology of symptoms and subsequent clinical course. Distinguish a discontinuation reaction from relapse or another acute illness. Do not use improvement after restarting as a stand-alone proof of causality.
21. Signal evaluation in a mature generic medicine
Escitalopram has been marketed for more than two decades and is supplied by many manufacturers. Spontaneous reports are shaped by the size of the treated population, stimulated reporting after safety communications, duplicate submissions, diagnostic changes and the use of other medicines. Raw report counts and disproportionality scores are not incidence rates and cannot by themselves establish causation.
A signal assessment should define a medically coherent event phenotype, review serious and well-documented cases, search for duplicate narratives, examine dose and exposure, compare with established labelling, and consider background disease risk and other medications. Population-based studies or mechanistic investigations may be needed where spontaneous reports cannot resolve confounding.
For escitalopram, potentially valuable review questions include whether a cardiac pattern clusters in patients with CYP2C19 inhibition, whether a specific error involves confusion with citalopram, whether reported persistent symptoms have sufficient longitudinal detail, and whether risk communication reaches people who start treatment or change dose. These are evaluation questions, not claims that new signals have been confirmed.
22. Regulatory governance, risk minimisation and evidence
EU pharmacovigilance responsibilities arise from applicable medicines legislation and implementing rules; GVP translates much of the operational framework into guidance [15,16]. In practice, a marketing-authorisation holder should preserve traceability from case intake and medical review through aggregate assessment, signal decisions, regulatory communication and effectiveness review where relevant. A QPPV needs a defensible account of who assessed an issue, what evidence was considered, what decision was reached and whether required actions were implemented.
The October 2026 MHRA communication is a concrete risk-minimisation case study: more prominent patient information and supporting materials are being introduced for established antidepressant risks [12,13]. The effectiveness question is not merely whether a revised leaflet exists. It is whether patients and professionals receive, understand and act on the information, and whether unintended consequences or gaps in communication emerge. Evaluating that effectiveness is a recommended governance approach, not an assertion that a specific new study is legally mandated for every escitalopram product.
An inspection-ready record would separate the legal obligation, the applicable guideline, the company's procedure, the evidence supporting a medical conclusion, and any corrective action. Do not present a hypothetical deficiency as a documented inspection finding.
23. Practical review checklist
For an escitalopram safety case or periodic benefit–risk review, verify the active substance and actual product; jurisdiction and authorised indication; age; formulation, dose and adherence; baseline psychiatric and cardiac history; CYP2C19 inhibitors and QT-prolonging drugs; objective event findings; treatment and outcome; and follow-up needs. For reproductive exposures, document the pregnancy and neonatal chronology. For psychiatric or sexual events, preserve the patient's account and the pre-treatment baseline.
Key Takeaways
Escitalopram's single-enantiomer origin is pharmacologically meaningful but does not substitute for clinical evidence. Adult depression trials, adolescent depression studies and paediatric GAD trials support different populations and regulatory decisions. US and UK product information differs materially, especially for paediatric use and the range of anxiety indications. Dose and exposure matter for QTc safety, while serotonergic interactions, hyponatraemia, bleeding, sexual adverse effects, discontinuation and pregnancy outcomes require their own clinical assessments. The most useful pharmacovigilance work connects precise phenotype → exposure and alternatives → regulatory context → documented decision → risk communication and learning.
References
- DailyMed / US National Library of Medicine. Escitalopram tablets, US prescribing information; updated 21 May 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6fbd554-9da7-40fd-87a5-2c4af2aa3e6c
- Electronic Medicines Compendium. Escitalopram 10 mg film-coated tablets, UK SmPC; eMC updated 28 May 2026. https://www.medicines.org.uk/emc/product/102179/smpc
- US Food and Drug Administration. Lexapro, NDA 21-323, original approval letter; 2002. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Approv.pdf
- McRae AL. Escitalopram H Lundbeck. Curr Opin Investig Drugs. 2002;3(8):1225–1229. https://pubmed.ncbi.nlm.nih.gov/12211420/
- Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63(4):331–336. https://pubmed.ncbi.nlm.nih.gov/12000207/
- Emslie GJ et al. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):721–729. https://pubmed.ncbi.nlm.nih.gov/19465881/
- Strawn JR et al. A multicenter double-blind, placebo-controlled trial of escitalopram in children and adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol. 2023;33(3). https://doi.org/10.1089/cap.2023.0004
-
Strawn JR et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry. 2020;81(5):20m13396. https://pubmed.ncbi.nlm.nih.gov/32857933/
-
US FDA. New Pediatric Labeling Information Database: Lexapro, MDD in adolescents; 19 March 2009. https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?id=14CE032258F71B7DE053564DA8C071F2&rownum=522&sd=labelingdatabase
- US FDA. Lexapro prescribing information: paediatric GAD; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s055%2C021365s039lbl.pdf
- MHRA. Citalopram and escitalopram: QT interval prolongation; December 2011 safety advice (web page dated 11 December 2014). https://www.gov.uk/drug-safety-update/citalopram-and-escitalopram-qt-interval-prolongation
- MHRA. Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction; 15 October 2026. https://www.gov.uk/drug-safety-update/antidepressants-new-safety-measures-for-all-patients-to-improve-communication-of-the-risk-of-suicidal-thoughts-and-behaviours-and-persistent-sexual-dysfunction
- MHRA. Antidepressants: use and safety; updated 15 October 2026. https://www.gov.uk/government/publications/antidepressants-use-and-safety--2
- DailyMed / US National Library of Medicine. Escitalopram generic label with paediatric-GAD exclusivity statement; 8 April 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2db02476-325f-ee47-a7e5-b5aed56c364c
- European Medicines Agency. Good pharmacovigilance practices (GVP); Modules VI and IX and subsequent updates. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
- European Medicines Agency. Legal framework: pharmacovigilance; EU directives, regulations and implementing rules. https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview/legal-framework-pharmacovigilance
Regulatory Note
Prepared 22 October 2026 using identified US and UK product labels, FDA regulatory records, primary clinical trials and MHRA/EMA materials. Current authorisation, age limits, dosing, contraindications and warnings must be verified for the specific marketed product and jurisdiction before clinical or regulatory action. The US boxed prescribing-information warning differs from the UK patient-leaflet boxed communication. Clinical trial effects, labelled risks, suspected individual reactions, post-marketing signals and recommended PV processes are distinct evidentiary categories. Illustrative cases are hypothetical.